

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

RANBAXY INC. and SUN PHARMACEUTICAL INDUSTRIES, LTD.,

Petitioners

v.

ADAMAS PHARMACEUTICALS, INC.,

Patent Owner

Inter Partes Review No.: 2015-00410

U.S. Patent No. 8,362,085

**Petitioners' Mandatory Notices – Updated Real Parties-in-Interest
37 C.F.R. § 42.8**

Petitioners Ranbaxy Inc. and Ranbaxy Laboratories Ltd. (n/k/a Sun Pharmaceutical Industries, Ltd.) (“Petitioners”) hereby provide notice of revised real parties-in-interest in this proceeding. These revised mandatory notices reflect that effective March 24, 2015, Petitioner Ranbaxy Laboratories, Ltd. merged with Sun Pharmaceutical Industries, Ltd. Sun Pharmaceutical Industries, Ltd. is the sole surviving entity of that merger and thus is a Petitioner in this proceeding. Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioners’ updated mandatory notices are below, reflecting these amendments.

I. MANDATORY NOTICES (37 C.F.R. § 42.8)

A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))

Ranbaxy Inc. and Sun Pharmaceutical Industries, Ltd are the real parties-in-interest for Petitioners.

Ranbaxy Inc. is not a publicly traded corporation, and is a wholly owned subsidiary of Ranbaxy Holdings (U.K.) Ltd., which is a wholly owned subsidiary of Ranbaxy (Netherlands) B.V., which in turn is wholly owned by Sun Pharmaceutical Industries, Ltd. Sun Pharmaceutical Industries, Ltd. is the only publicly traded parent company of Ranbaxy, Inc. Sun Pharmaceutical Industries, Ltd. is a publicly traded corporation, and no parent company or publicly traded corporation owns 10% or more of Sun Pharmaceutical Industries, Ltd.’s stock.

B. Related Matters (37 C.F.R. § 42.8(b)(2))

Petitioners are not aware of any reexamination certificates or pending prosecution concerning the '085 patent. Petitioners are parties to a pending litigation regarding infringement and invalidity of the '085 patent, namely *Forest Laboratories, Inc. et al v. Ranbaxy Inc. et. al*, Civ. Action No. 14-cv-686, currently pending in the District of Delaware. There are also pending litigations regarding infringement and invalidity of the '085 patent currently pending against additional parties in the District of Delaware, including Civ. Action Nos. 14-cv-121, 14-cv-200, 14-cv-508, 14-cv-1058, and 14-cv-1271.

There are also two pending applications claiming benefit to the '085 patent, namely No. 14/081,643, filed on November 15, 2013, and No. 14/339,599, filed on July 24, 2014.

C. Identification of Counsel (37 C.F.R. § 42.8(b)(3))

Lead Counsel	Back-up Counsel
John W. Bateman (Reg. No. 41,602) KENYON & KENYON LLP 1500 K Street, NW Washington, DC 20005 jbateman@kenyon.com Tel: 202.220.4216 Fax: 202.220.4201	Karen C. Shen (Reg. No. 60,412) KENYON & KENYON LLP One Broadway New York, NY 10004-1007 kshen@kenyon.com Tel: 212.908.6206 Fax: 212.425.5288

D. Service Information (37 C.F.R. § 42.8(b)(4))

Please direct all correspondence to lead counsel and back-up counsel at the

contact information above. Petitioners consent to service by electronic mail at jbateman@kenyon.com and kshen@kenyon.com.

Dated: April 8, 2015



John W. Bateman
(Reg. No. 41,602)
KENYON & KENYON LLP
1500 K Street, NW
Washington, DC 20005
jbateman@kenyon.com
Tel: 202.220.4216
Fax: 202.220.4201


CERTIFICATE OF SERVICE

The undersigned hereby confirms that the foregoing *Petitioners' Mandatory Notices – Updated Real Parties-in-Interest* was served on April 8, 2015 via e-mail upon the following counsel of record for the Patent Owner.

Peter J. Armenio, P.C.
QUINN EMMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue
22nd Floor
New York, NY 10010

Evangeline L. Shih
QUINN EMMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue
22nd Floor
New York, NY 10010

Dated: April 8, 2015



Hannah Rose Stein
KENYON & KENYON LLP
One Broadway
New York, NY 10004-1007
hstein@kenyon.com
Tel: 212.908.6398
Fax: 212.425.5288